Analyst Price Target is $4.25
▲ +245.53% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cellectar Biosciences in the last 3 months. The average price target is $4.25, with a high forecast of $5.50 and a low forecast of $3.00. The average price target represents a 245.53% upside from the last price of $1.23.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Cellectar Biosciences. This Buy consensus rating has held steady for over two years.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.